Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
EKF Diagnostics Holdings (GB:EKF)
:EKF
Holding GB:EKF?
Track your performance easily
EKF Stock Chart & Stats
Day’s Range― - ―
52-Week Range23.00p - 34.00p
Previous CloseN/A
Volume8.60K
Average Volume (3M)383.47K
Market Cap
£116.61M
Enterprise Value122.78M
Total Cash (Recent Filing)$7.87M
Total Debt (Recent Filing)$1.13M
Price to Earnings (P/E)24.5
Beta0.28
Next Earnings
Apr 01, 2025EPS Estimate
0.8Last Dividend Ex-Date
Nov 02, 2023Dividend Yield4.67%
Share Statistics
EPS (TTM)0.01
Shares Outstanding453,730,560
10 Day Avg. Volume219,086
30 Day Avg. Volume383,471
Standard Deviation0.13
R-Squared0.00391
Alpha0.00571
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.05
Price to Cash Flow (P/CF)23.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.92
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EKF Diagnostics Holdings News
PremiumCompany Announcements
EKF Diagnostics Boasts Strong Mid-Year Financials
PremiumCompany Announcements
EKF Diagnostics Announces Upcoming Interim Results
PremiumCompany Announcements
EKF Diagnostics Boasts Strong Mid-Year Financials
PremiumCompany Announcements
EKF Diagnostics Unveils Upgraded Analyzer and Wins Contracts
PremiumCompany Announcements
EKF Diagnostics Shareholders Approve AGM Resolutions
PremiumCompany Announcements
EKF Diagnostics Projects Strong Growth in 2024
PremiumCompany Announcements
EKF Diagnostics Sees Robust Growth in Early 2024PremiumCompany Announcements
EKF Diagnostics Announces AGM and Annual ReportOptions Prices
Currently, No data available
---
Ownership Overview
29.17% Insiders
0.12% Mutual Funds
― Other Institutional Investors
70.48% Public Companies and
Individual Investors
EKF FAQ
What was EKF Diagnostics Holdings’s price range in the past 12 months?
EKF Diagnostics Holdings lowest share price was 23.00p and its highest was 34.00p in the past 12 months.
What is EKF Diagnostics Holdings’s market cap?
EKF Diagnostics Holdings’s market cap is £116.61M.
When is EKF Diagnostics Holdings’s upcoming earnings report date?
EKF Diagnostics Holdings’s upcoming earnings report date is Apr 01, 2025 which is in 73 days.
How were EKF Diagnostics Holdings’s earnings last quarter?
EKF Diagnostics Holdings released its earnings results on Sep 17, 2024. The company reported 0.005p earnings per share for the quarter, the consensus estimate of 0.005p by 0p.
Is EKF Diagnostics Holdings overvalued?
According to Wall Street analysts EKF Diagnostics Holdings’s price is currently Overvalued.
Does EKF Diagnostics Holdings pay dividends?
EKF Diagnostics Holdings pays a Annually dividend of 1.2p which represents an annual dividend yield of 4.67%. See more information on EKF Diagnostics Holdings dividends here
What is EKF Diagnostics Holdings’s EPS estimate?
EKF Diagnostics Holdings’s EPS estimate is 0.8.
How many shares outstanding does EKF Diagnostics Holdings have?
EKF Diagnostics Holdings has 453,730,560 shares outstanding.
What happened to EKF Diagnostics Holdings’s price movement after its last earnings report?
EKF Diagnostics Holdings reported an EPS of 0.005p in its last earnings report, expectations of 0.005p. Following the earnings report the stock price went down -0.909%.
Which hedge fund is a major shareholder of EKF Diagnostics Holdings?
Currently, no hedge funds are holding shares in GB:EKF
---
EKF Diagnostics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.47%
12-Months-Change
Fundamentals
Return on Equity
7.18%
Trailing 12-Months
Asset Growth
-3.55%
Trailing 12-Months
Company Description
EKF Diagnostics Holdings
EKF Diagnostics Holdings PLC is engaged in the field of medical diagnostics. The company core business is point-of-care testing and to manufacture reagents for use in central laboratories. It caters to companies focused on areas such as diabetes, blood banking, and sports medicine. The company derives most of its income from its sales in the United States. Its other markets include Germany, Poland, and Russia.
---
Technical Analysis
Abingdon Health PLC
―
HemoGenyx Pharmaceuticals Plc
―
Genus plc
―
Synairgen
―
Trellus Health PLC
―
Creo Medical
―
---